220 related articles for article (PubMed ID: 21177406)
1. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden.
Creaney J; Francis RJ; Dick IM; Musk AW; Robinson BW; Byrne MJ; Nowak AK
Clin Cancer Res; 2011 Mar; 17(5):1181-9. PubMed ID: 21177406
[TBL] [Abstract][Full Text] [Related]
2. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
Roe OD; Creaney J; Lundgren S; Larsson E; Sandeck H; Boffetta P; Nilsen TI; Robinson B; Kjaerheim K
Lung Cancer; 2008 Aug; 61(2):235-43. PubMed ID: 18281122
[TBL] [Abstract][Full Text] [Related]
3. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
[TBL] [Abstract][Full Text] [Related]
4. Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.
Wheatley-Price P; Yang B; Patsios D; Patel D; Ma C; Xu W; Leighl N; Feld R; Cho BC; O'Sullivan B; Roberts H; Tsao MS; Tammemagi M; Anraku M; Chen Z; de Perrot M; Liu G
J Clin Oncol; 2010 Jul; 28(20):3316-22. PubMed ID: 20498407
[TBL] [Abstract][Full Text] [Related]
5. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma.
Hollevoet K; Nackaerts K; Gosselin R; De Wever W; Bosquée L; De Vuyst P; Germonpré P; Kellen E; Legrand C; Kishi Y; Delanghe JR; van Meerbeeck JP
J Thorac Oncol; 2011 Nov; 6(11):1930-7. PubMed ID: 21841505
[TBL] [Abstract][Full Text] [Related]
6. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma.
Shiomi K; Hagiwara Y; Sonoue K; Segawa T; Miyashita K; Maeda M; Izumi H; Masuda K; Hirabayashi M; Moroboshi T; Yoshiyama T; Ishida A; Natori Y; Inoue A; Kobayashi M; Sakao Y; Miyamoto H; Takahashi K; Hino O
Clin Cancer Res; 2008 Mar; 14(5):1431-7. PubMed ID: 18316566
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
[TBL] [Abstract][Full Text] [Related]
8. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P
Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993
[TBL] [Abstract][Full Text] [Related]
9. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
Scherpereel A; Grigoriu B; Conti M; Gey T; Grégoire M; Copin MC; Devos P; Chahine B; Porte H; Lassalle P
Am J Respir Crit Care Med; 2006 May; 173(10):1155-60. PubMed ID: 16456138
[TBL] [Abstract][Full Text] [Related]
10. Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment.
Grigoriu BD; Chahine B; Vachani A; Gey T; Conti M; Sterman DH; Marchandise G; Porte H; Albelda SM; Scherpereel A
Am J Respir Crit Care Med; 2009 May; 179(10):950-4. PubMed ID: 19201924
[TBL] [Abstract][Full Text] [Related]
11. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos.
Gube M; Taeger D; Weber DG; Pesch B; Brand P; Johnen G; Müller-Lux A; Gross IM; Wiethege T; Weber A; Raithel HJ; Kraus T; Brüning T
Arch Toxicol; 2011 Mar; 85(3):185-92. PubMed ID: 20737138
[TBL] [Abstract][Full Text] [Related]
12. ERC/mesothelin as a marker for chemotherapeutic response in patients with mesothelioma.
Tajima K; Hirama M; Shiomi K; Ishiwata T; Yoshioka M; Iwase A; Iwakami S; Yamazaki M; Toba M; Tobino K; Sugano K; Ichikawa M; Hagiwara Y; Takahashi K; Hino O
Anticancer Res; 2008; 28(6B):3933-6. PubMed ID: 19192652
[TBL] [Abstract][Full Text] [Related]
13. Soluble mesothelin-related protein--a blood test for mesothelioma.
Robinson BW; Creaney J; Lake R; Nowak A; Musk AW; de Klerk N; Winzell P; Hellstrom KE; Hellstrom I
Lung Cancer; 2005 Jul; 49 Suppl 1():S109-11. PubMed ID: 15950789
[TBL] [Abstract][Full Text] [Related]
14. Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.
Burt BM; Lee HS; Lenge De Rosen V; Hamaji M; Groth SS; Wheeler TM; Sugarbaker DJ
Ann Thorac Surg; 2017 Nov; 104(5):1679-1687. PubMed ID: 28964420
[TBL] [Abstract][Full Text] [Related]
15. Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans.
Liu F; Zhao B; Krug LM; Ishill NM; Lim RC; Guo P; Gorski M; Flores R; Moskowitz CS; Rusch VW; Schwartz LH
J Thorac Oncol; 2010 Jun; 5(6):879-84. PubMed ID: 20421814
[TBL] [Abstract][Full Text] [Related]
16. Is serum thioredoxin-1 a useful clinical marker for malignant pleural mesothelioma?
Maeda R; Tabata C; Tabata R; Eguchi R; Fujimori Y; Nakano T
Antioxid Redox Signal; 2011 Aug; 15(3):685-9. PubMed ID: 21375472
[TBL] [Abstract][Full Text] [Related]
17. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.
Ceresoli GL; Chiti A; Zucali PA; Rodari M; Lutman RF; Salamina S; Incarbone M; Alloisio M; Santoro A
J Clin Oncol; 2006 Oct; 24(28):4587-93. PubMed ID: 17008700
[TBL] [Abstract][Full Text] [Related]
18. Use of Serum Mesothelin as an Indicator of Tumor Progression in Routine Clinical Practice of Malignant Pleural Mesothelioma Treatment.
Vigani A; Pistillo MP; Fontana V; Giannoni U; Rosenberg I; Canessa PA; Berisso G; Ferro P; Franceschini MC; Tonarelli M; Roncella S
J Thorac Oncol; 2018 Aug; 13(8):e143-e145. PubMed ID: 30049376
[No Abstract] [Full Text] [Related]
19. Mesothelin and kidney function--analysis of relationship and implications for mesothelioma screening.
Boudville N; Paul R; Robinson BW; Creaney J
Lung Cancer; 2011 Sep; 73(3):320-4. PubMed ID: 21333373
[TBL] [Abstract][Full Text] [Related]
20. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications.
Erasmus JJ; Truong MT; Smythe WR; Munden RF; Marom EM; Rice DC; Vaporciyan AA; Walsh GL; Sabloff BS; Broemeling LD; Stevens CW; Pisters KM; Podoloff DA; Macapinlac HA
J Thorac Cardiovasc Surg; 2005 Jun; 129(6):1364-70. PubMed ID: 15942579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
